Guardant Reveal
Home » Guardant Reveal™

Guardant-Reveal

Residual disease detection and recurrence monitoring*

Guardant RevealTM is the first blood-only test that is able to detect residual and recurrent disease in two weeks, without the need for a tissue biopsy. The test detects circulating tumor DNA (ctDNA) in blood to inform treatment decisions after surgery and detect recurrence as well. Currently, it is developed for early-stage colorectal cancer with testing for additional cancer types to follow.

*Please speak to your physician to find out whether the Guardant Reveal test is appropriate for you.

The blood-only liquid biopsy test for minimal residual disease detection & recurrence monitoring

Guardant Reveal detects circulating tumor DNA (ctDNA) for minimal residual disease (MRD) assessment in patients with Stage II and Stage III colorectal cancer (CRC). In addition to detection of MRD, Guardant Reveal can be ­­used to monitor for recurrence of CRC in previously diagnosed patients.

Guardant Reveal for patients with Stage II/III CRC

Post-Surgery

Identify patients at high risk for recurrence

Surveillance

Monitor for early signs of recurrence

Delivering fast, reliable test results

Guardant Reveal delivers results in two weeks and does not require tissue to initiate, eliminating the delays associated with assays that require tissue and the challenge of inadequate tissue samples. In addition, Guardant Reveal can be ordered 4 weeks after surgery.

References :

  1. Tsikitis, V.L., Larson, D.W., Huebner, M. et al. Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer 14, 336 (2014). https://doi.org/10.1186/1471-2407-14-336
  2. Parikh A, Van Seventer E, Siravegna G, Hartwig A, et al Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-21-0410
Open chat
Message us
Guardant Reveal™ - Guardant Health AMEA

Guardant Reveal
Home » Guardant Reveal™

Guardant-Reveal

Residual disease detection and recurrence monitoring*

Guardant RevealTM is the first blood-only test that is able to detect residual and recurrent disease in two weeks, without the need for a tissue biopsy. The test detects circulating tumor DNA (ctDNA) in blood to inform treatment decisions after surgery and detect recurrence as well. Currently, it is developed for early-stage colorectal cancer with testing for additional cancer types to follow.

*Please speak to your physician to find out whether the Guardant Reveal test is appropriate for you.

The blood-only liquid biopsy test for minimal residual disease detection & recurrence monitoring

Guardant Reveal detects circulating tumor DNA (ctDNA) for minimal residual disease (MRD) assessment in patients with Stage II and Stage III colorectal cancer (CRC). In addition to detection of MRD, Guardant Reveal can be ­­used to monitor for recurrence of CRC in previously diagnosed patients.

Guardant Reveal for patients with Stage II/III CRC

Post-Surgery

Identify patients at high risk for recurrence

Surveillance

Monitor for early signs of recurrence

Delivering fast, reliable test results

Guardant Reveal delivers results in two weeks and does not require tissue to initiate, eliminating the delays associated with assays that require tissue and the challenge of inadequate tissue samples. In addition, Guardant Reveal can be ordered 4 weeks after surgery.

References :

  1. Tsikitis, V.L., Larson, D.W., Huebner, M. et al. Predictors of recurrence free survival for patients with stage II and III colon cancer. BMC Cancer 14, 336 (2014). https://doi.org/10.1186/1471-2407-14-336
  2. Parikh A, Van Seventer E, Siravegna G, Hartwig A, et al Minimal Residual Disease Detection using a Plasma-Only Circulating Tumor DNA Assay in Colorectal Cancer Patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.CCR-21-0410
Open chat
Message us